George Scangos is to step down as the chief executive of US biotech major Biogen, it was announced on Thursday, when the company also revealed results for 2016’s second quarter which exceeded analysts’ expectations. 21 July 2016
Ireland-incorporated Perrigo has announced that Douglas Boothe, the general manager of its Rx Pharmaceuticals segment, is leaving the company. 21 July 2016
The pharmaceutical industry’s use of directors from outside the sector has fallen from 40% to 26% in the last five years, research from executive search firm DHR International shows. 12 July 2016
Taro Pharmaceutical Industries announced today that its chief executive, Kalyanasundaram (Kal) Sundaram, has informed Taro’s board of directors of his intention to step down as CEO by the end of the current calendar year. 7 July 2016
China-based biopharma firm CStone Pharmaceuticals says it has closed its Series A round of $150 million dollars financing (about 975 million renminbi). 4 July 2016
USA-based generic pharmaceutical company G & W Laboratories has announced the appointment of Jay Galeota to the position of president and chief operating officer. 30 June 2016
Edward Jensen, the new chief operating officer at US-based Blueprint Bio, has described his excitement at being part of "arguably the most groundbreaking" venture in health care. 27 June 2016
Aimmune Therapeutics, a US-based biopharma company developing treatments for life-threatening food allergies, has appointed Daniel Adelman its new chief medical officer. 23 June 2016
Murdo Gordon has been appointed executive vice president and chief commercial officer, a newly-created position, at US pharma major Bristol-Myers Squibb, effective June 21, 2016. 22 June 2016
A former heavyweight at US health care giant Johnson & Johnson has been named in a key position with Biogen to lead the biotech company’s growth in development and manufacturing. 22 June 2016
Shares in British drugmaker GlaxoSmithKline (LON: GSK) fell some 2.35% in Tuesday trading, on the news that the company's vaccines boss, Moncef Slauoi, is to retire in June 2017. 15 June 2016
Shareholders of German family-owned pharma major Boehringer Ingelheim have decided to appoint Simone Menne to the firm’s board of managing directors with effect from September 1, 2016. 10 June 2016
The US District Court for the District of Delaware has issued a claim construction (Markman) ruling governing patent litigation brought by Orexigen Therapeutics and Japan’s Takeda Pharmaceutical against Andrx and Actavis (now Allergan) companies. 10 June 2016
German family-owned drugmaker Grünenthal Group today announced that its supervisory board has named Gabriel Baertschi to become Grünenthal’s new chief executive as of October 1, 2016. 7 June 2016
Germany’s Merck (MRK: DE) and US pharma giant Pfizer (NYSE: PFE) plan to file for accelerated approval of avelumab for the treatment of patients with metastatic merkel cell carcinoma (MCC), it has been revealed. 6 June 2016
Embattled drug company Valeant has named Tyco International executive Sam Eldessouky as corporate controller and a senior vice president as it tries rebuild its reputation after a string of controversies. 27 May 2016
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024